Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The FDA has approved an intravenous version of Boniva, a treatment for postmenopausal osteoporosis co-promoted by Roche and GlaxoSmithKline.
Subscribe to our email newsletter
This approval of the intravenous form of the drug will provide an alternative for patients who have difficulty with oral bisphosphonate dosing requirements, including an inability to sit upright for 30 to 60 minutes and/or swallow a pill. The tablet version of the drug was approved by the FDA in March 2005.
Additionally, because Boniva injection will be administered by healthcare professionals, clinicians will have a greater awareness of patient compliance with therapy.
Boniva injection was approved by the FDA based on results of a clinical trial in 1,358 women with postmenopausal osteoporosis.
“(Boniva) represents an important new opportunity to bring the bone-strengthening benefits of Boniva to more women – including those who have difficulty with dosing requirements of oral bisphosphonates,” said Dr Robert Recker, director of Creighton University Osteoporosis Research Center, Omaha.